Scleroderma Foundation Research Grant Program
|Application Deadline for All Grant Proposals Extended to September 30, 2021|
|NEWS: 2022 Funding Level Increases to $2.723 Million|
In June of 2021, the Scleroderma Foundation announced an increase of its peer-reviewed scientific research funding to $2.723 million annually, more than doubling our commitment. In addition to the increase in funding made available, the Foundation is also increasing the amount of the grant awards to $200,000 per award.
The Scleroderma Foundation is the leading nonprofit supporter of peer-reviewed, scleroderma research to discover the cause, understand the mechanism, and overcome scleroderma forever. Since its inception, the Foundation has committed over $30 million for scleroderma research, which continues as a priority of our mission.
New Grant Opportunities Announced for the 2022 Grant Cycle
The increase of annual research funds allows the Foundation to expand on the current Established and New Investigator grant opportunities and offer additional grants for proposals in two key areas:
Scleroderma-Related Lung Disease — The NEW Debra Lurvey Memorial Research Grant, funded by a generous donor, will be awarded in the amount of $200,000 to an established investigator conducting scleroderma-related lung disease research.
Pediatric Scleroderma — Pediatric scleroderma research is earmarked for up to $500,000 in awards and is open to submissions from both new and established investigators.
The Scleroderma Foundation continues to fund both New and Established Investigator Grants for all other scleroderma-related research proposals.
To view all available grant opportunities, go to: Apply for a Research Grant.
Researchers interested in the grant program should review the "How to Apply" section, which includes information about appropriate areas of research, restrictions, review criteria and more.
The Foundation’s Peer-Review Research Grant Funding Program has earned a unique place in the field of scleroderma research. It is respected by medical researchers and by government health agencies such as National Institutes of Health (NIH) and National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The program is administered by the Scleroderma Foundation's Board of Directors and staff, and guided by the Foundation's Peer Research Review Committee. This committee, composed of scleroderma medical experts from around the world, helps determine which proposals will be funded each year by reading, critiquing, and ranking all applications.
The Future of Scleroderma Research
Thanks to recent advances in research and treatment, individuals who have scleroderma as a group can now expect to live longer and more productive lives with increased hope for the future.
A cure for scleroderma, however, remains an elusive goal. Research costs continue to climb. Modern laboratory staff, equipment, and supplies are expensive. Laboratories and clinical research programs must look outside their own facilities for financial support.
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of NIH, provides funding for the majority of scleroderma research. Although NIH grants to scleroderma researchers have increased in recent years, scleroderma funding is still a relatively low priority.
The Scleroderma Foundation has a critically important role as catalyst to fund and to stimulate new research and new ideas. The Foundation is enlisting the support of legislators and other decision makers to establish a higher profile for scleroderma and the needs of patients.
The key to all our efforts, to ensure that productive research moves forward, is the continued generosity of our individual and corporate donors.